2018 NDAs: Living In The Wake Of 2017
Source: Life Science Leader
By ISR
With 46 new drugs approved in 2017 (51 if you include five biosimilars), we see that the pharma industry was quite busy. The number of new drug approvals more than doubled from 2016’s level of 22, which begs the question: What is the knock-on effect of a near-record volume of approvals? When one thinks about the potential impact on manufacturing, market access, late-phase clinical development, and sales and marketing activities, the impact is likely substantial.
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more